Prospects for active immunotherapies for hepatitis B virus chronic carriers

Research in Virology

Volumn 148, Issue 2, 1997, Pages 95-99

  Michel, M L ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

chronic carriers; gene therapy; HBV; immunotherapy; lipopolypeptides; review; viral vectors

Indexed keywords

HEPATITIS B VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA INTERFERON;

CONFERENCE PAPER; DRUG EFFICACY; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL;

HEPATITIS B VIRUS;

EID: 0030943757     PISSN: 09232516     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2516(97)89891-3     Document Type: Conference Paper

References (22)

1. Brook, M.G., Karayiannis, P. & Thomas, H.C. (1989), Which patients with chronic hepatitis B virus infection will respond to alpha interferon therapy? A statistical analysis of predictive factors. Hepatology, 10, 761-763.
2. Chisari, F.V. (1995), Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol., 13, 29-60.
3. Chu, C.M., Karayiannis, P., Fowler, M.J.F., Monjardino, J., Liaw, Y.F. & Thomas, H.C. (1985), Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology, 5, 431-434.
4. Colombo, M. (1992), Hepatocellular carcinoma. J. Hepatol., 15, 225-236.
5. De Franchis, R., Meucci, G., Vecchi, M., Tatarella, M., Colombo, M., Del Ninno, E., Rumi, M., Donato, M. & Ronchi, G. (1993), The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med., 118, 191-194.
6. Farza, H., Salmon, A.-M., Hadchouel, M., Moreau, J.-L., Babinet, C., Tiollais, P. & Pourcel, C. (1987), Hepatitis B surface antigen gene expression is regulated by sex-steroids and glucocorticoids in transgenic mice. Proc. Natl. Acad. Sci. USA, 84, 1187-1191.
7. He, X.-S., Chen, H.-S., Chu, K., Rivkina, M. & Robinson, W.S. (1996), Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA, 93, 7274-7278.
8. Mancini, M., Hadchouel, M., Davis, H.L., Whalen, R.G., Tiollais, P. & Michel, M.-L. (1996), DNA-mediated immunization in a transgenique mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl. Acad. Sci. USA (in press).
9. Mancini, M., Hadchouel, M., Tiollais, P., Pourcel, C. & Michel, M.-L. (1993), Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg transgenic mice: a possible way of circumventing "non-response" to HBsAg. J. Med. Virol., 39, 67-74.
10. Maruyama, T., McLachlan, A., Lino, S., Koike, K., Kurokawa, K. & Milich, D.R. (1993), The serology of chronic hepatitis B infection revisited. J. Clin. Invest., 91, 2586-2595.
11. Michel, M.-L. (1995), DNA-mediated immunization: prospects for hepatitis B vaccination. Res. Virol., 146, 261-265.
12. Milich, D.R., McLachlan, A., Thornton, G.B. & Hughes, J.L. (1987), Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature (Lond.), 329, 547-549.
13. Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C., Mohr, L. & Häussinger, D. (1996), Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med., 334, 1422-1427.
14. Pol, S., Driss, F., Carnot, F., Michel, M.-L., Berthelot, P. & Brechot, C. (1993), Vaccination against hepatitis B virus: an efficient immunotherapy against hepatitis B multiplication. C. R. Acad. Sci. Paris, 316, 688-691.
15. Pol, S., Driss, F., Michel, M.-L., Nalpas, B., Berthelot, P. & Brechot, C. (1994), Specific vaccine therapy in chronic hepatitis B infection. Lancet, 344, 342.
16. Pol, S., Maincent, G., Michel, M.-L., Driss, F., Nalpas, B., Carnot, F., Berthelot, P. & Brechot, C. (1996), Immunotherapy of chronic hepatitis B anti HBV vaccine, in "Viral Hepatitis and Liver Disease" (M. Rizzetto) (in press).
17. Ronlov, G., Anderson, C.-G., Townsend, K., O'Dea, J., Sallberg, M., Milich, D.R., Chang, S.M.W., Jolly, D. & Lee, W.T.L. (1996), Direct injection of a recombinant retroviral vector expressing HBV core in chronic carrier chimpanzees, in "Abstract of papers presented at the 1996 Meeting on Molecular Biology of Hepatitis B Viruses at Cold Spring Harbor, 18-22 September 1996" (pp. 164). Cold Spring Harbor Laboratory, New York.
18. Sylvan, S.P.E., Hellstrom, U.B. & Lundbergh, P.R. (1985), Detection of cellular and humoral immunity to hepatitis B surface antigen (HBsAg) in asymptomatic HBsAg carriers. Clin. Exp. Immunol., 62, 288-295.
19. Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K.I.F., Inoue, A., Yamazaki, I. & Kawashima, T. (1993), Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med., 328, 1797-1801.
20. Ulmer, J.B., Donnelly, J.J. & Liu, M.A. (1994), Vaccination with polynucleotides: a novel means of generating immunity, in "Modern vaccinology" (E. Kurstak) (pp. 13-23). Plenum Medical, New York.
21. Vitiello, A., Ishioka, G., Grey, H.M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F.V., Furze, J., Bartholomeuz, R. & Chesnut, R.W. (1995), Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. - I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest., 95, 341-349.
22. Wright, L. & Lau, J.Y.N. (1993), Clinical aspects of hepatitis B virus infection. Lancet, 342, 1340-1344.